Assembly Biosciences
ASMB
113 hedge funds and large institutions have $801M invested in Assembly Biosciences in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 20 reducing their positions, and 15 closing their positions.
323% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $2.9M
195% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 20
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
25% more capital invested
Capital invested by funds: $640M → $801M (+$161M)
8% more funds holding
Funds holding: 105 → 113 (+8)
0.35% more ownership
Funds ownership: 6.74% → 7.09% (+0.35%)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$79.7M |
| 2 |
BlackRock
New York
|
+$23.6M |
| 3 |
O
OrbiMed
New York
|
+$20M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$15.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$11.8M |
Top Sellers
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$9.06M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.94M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.91M |
| 4 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$5.89M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.88M |
ASMB Hedge Fund Activity: Q3 2018 in Review
113 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2018, worth a combined $801M — up 25% from $640M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ASMB positions and 15 closed out — a net gain of 8 holders — while 59 added to existing stakes and 20 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $79.7M. The largest seller was Acuta Capital Partners, cutting an estimated $9.06M.
- 113 institutional investors held Assembly Biosciences (ASMB) as of Q3 2018, up from 105 in Q2 2018.
- Funds reported $801M of Assembly Biosciences stock for Q3 2018, up 25% quarter-over-quarter.
- 23 funds opened new Assembly Biosciences positions in Q3 2018 and 15 closed out, a net change of +8 holders.
- The largest Assembly Biosciences buyer in Q3 2018 was Wellington Management Group, an estimated $79.7M added.
- The largest Assembly Biosciences seller in Q3 2018 was Acuta Capital Partners, an estimated $9.06M sold.
Based on aggregated 13F filings for Q3 2018.